Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1 - 42), Tau, and phosphorylated Tau in Alzheimer's disease: Report of an international workshop

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Teunissen, Charlotte E ^a   Verwey, Niek A ^a   Kester, Maartje I ^a   Van Uffelen, Kees ^a   Blankenstein, Marinus A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FINISHING; HUMAN; INCUBATION; PIPETTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SAMPLE HANDING; STANDARDIZATION; WASHING;

EID: 78349265011     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/635053     Document Type: Article

References (8)

1. Mount C., Downton C., Alzheimer disease: progress or profit? Nature Medicine 2006 12 7 780 784
2. Knopman D. S., DeKosky S. T., Cummings J. L., Chui H., Corey-Bloom J., Relkin N., Small G. W., Miller B., Stevens J. C., Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology Neurology 2001 56 9 1143 1153
3. Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nature Reviews Neurology 2010 6 3 131 144
4. Mulder C., Verwey N. A., van der Flier W. M., Bouwman F. H., Kok A., Van Elk E. J., Scheltens P., Blankenstein M. A., Amyloid- (1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease Clinical Chemistry 2010 56 2 248 253
5. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.-K., Van Der Flier W. M., Blankenstein M. A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosn E., Aarsland D., Jelle Visser P., Schrder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Pirttil T., Wallin A., Eriksdotter Jnhagen M., Minthon L., Winblad B., Blennow K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Journal of the American Medical Association 2009 302 4 385 393
6. Verwey N. A., van der Flier W. M., Blennow K., Clark C., Sokolow S., De Deyn P. P., Galasko D., Hampel H., Hartmann T., Kapaki E., Lannfelt L., Mehta P. D., Parnetti L., Petzold A., Pirttila T., Saleh L., Skinningsrud A., V Swieten J. C., Verbeek M. M., Wiltfang J., Younkin S., Scheltens P., Blankenstein M. A., A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Annals of Clinical Biochemistry 2009 46, part 3 235 240
7. Schoonenboom N. S. M., Mulder C., Vanderstichele H., Van Elk E.-J., Kok A., Van Kamp G. J., Scheltens P., Blankenstein M. A., Effects of processing and storage conditions on amyloid (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice Clinical Chemistry 2005 51 1 189 195
8. Teunissen C. E., Petzold A., Bennett J. L., Berven F. S., Brundin L., Comabella M., Franciotta D., Frederiksen J. L., Fleming J. O., Furlan R., Hintzen R. Q., Hughes S. G., Johnson M. H., Krasulova E., Kuhle J., Magnone M. C., Rajda C., Rejdak K., Schmidt H. K., Van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking Neurology 2009 73 22 1914 1922